Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

123 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomised open-label parallel group four months comparison in patients with type 2 diabetes.
Ligthelm RJ, Mouritzen U, Lynggaard H, Landin-Olsson M, Fox C, le Devehat C, Romero E, Liebl A. Ligthelm RJ, et al. Among authors: liebl a. Exp Clin Endocrinol Diabetes. 2006 Oct;114(9):511-9. doi: 10.1055/s-2006-924424. Exp Clin Endocrinol Diabetes. 2006. PMID: 17115349 Clinical Trial.
Three different premixed combinations of biphasic insulin aspart - comparison of the efficacy and safety in a randomized controlled clinical trial in subjects with type 2 diabetes.
Cucinotta D, Smirnova O, Christiansen JS, Kanc K, le Devehat C, Wojciechowska M, López de la Torre M, Liebl A. Cucinotta D, et al. Among authors: liebl a. Diabetes Obes Metab. 2009 Jul;11(7):700-8. doi: 10.1111/j.1463-1326.2009.01035.x. Epub 2009 May 19. Diabetes Obes Metab. 2009. PMID: 19476479 Clinical Trial.
The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries.
Khunti K, Caputo S, Damci T, Dzida GJ, Ji Q, Kaiser M, Karnieli E, Liebl A, Ligthelm RJ, Nazeri A, Orozco-Beltran D, Pan C, Ross SA, Svendsen AL, Vora J, Yale JF, Meneghini LF; SOLVE Study Group. Khunti K, et al. Among authors: liebl a. Diabetes Obes Metab. 2012 Dec;14(12):1129-36. doi: 10.1111/j.1463-1326.2012.01665.x. Epub 2012 Aug 30. Diabetes Obes Metab. 2012. PMID: 22830956
A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial.
Heise T, Tack CJ, Cuddihy R, Davidson J, Gouet D, Liebl A, Romero E, Mersebach H, Dykiel P, Jorde R. Heise T, et al. Among authors: liebl a. Diabetes Care. 2011 Mar;34(3):669-74. doi: 10.2337/dc10-1905. Epub 2011 Feb 1. Diabetes Care. 2011. PMID: 21285389 Free PMC article. Clinical Trial.
Practical guidance to insulin management.
Meneghini L, Artola S, Caputo S, Damci T, Dzida G, Kaiser M, Khunti K, Liebl A, Ligthelm R, Maran A, Orozco-Beltran D, Ross S, Yale JF. Meneghini L, et al. Among authors: liebl a. Prim Care Diabetes. 2010 Apr;4 Suppl 1:S43-56. doi: 10.1016/S1751-9918(10)60008-3. Prim Care Diabetes. 2010. PMID: 20394891
123 results